Anita K. McElroy, MD, PhD
- Assistant Professor, Department of Pediatrics
Education & Training
- MD, George Washington University, 2007
- PhD in Biology, University of California San Diego, 2000
- BS in Microbiology, University of Maryland, 1996
We study the interactions that occur between the host and emerging viral pathogens with a focus on host immune responses. To do this, animal model systems, clinical specimens from cases of human disease, and in vitro models are used. Previous work has focused on the Hantaviruses, Rift Valley fever virus (RVFV), Crimean-Congo hemorrhagic fever virus, Ebola virus and Lassa virus. Current studies are targeted towards RVFV and include the use of genetically out-bred mice to understand the role of host genetics in clinical disease manifestations, establishing the mechanistic correlates of vaccine mediated protection, and evaluating the role of viral tropism in RVFV disease.
McElroy AK, Harmon JR, Flietstra T, Nichol ST and Spiropoulou CF. 2018. Human Biomarkers of Outcome Following Rift Valley Fever Virus Infection. J Infect Dis. 218: 1847-1851.
Harmon JR, Spengler JR, Coleman-McCray JD, Nichol ST, Spiropoulou CF and McElroy AK. 2018. CD4 T Cells, CD8 T Cells, and Monocytes Coordinate To Prevent Rift Valley Fever Virus Encephalitis. J Virol. 92: pii: e01270-18.
Harmon JR, Barbeau DJ, Nichol ST, Spiropoulou CF and McElroy AK. 2020. Rift Valley fever virus vaccination induces long-lived, antigen-specific human T cell responses. NPJ Vaccines. In press.
McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS, Lyon GM, Ribner BS, Varkey J, Sidney J, Sette A, Campbell S, Stroher U, Damon I, Nichol ST, Spiropoulou CF and Ahmed R. 2015. Human Ebola virus infection results in substantial immune activation. Proc Natl Acad Sci USA. 112: 4719-4724.
McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS and Spiropoulou CF. 2014. Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome. J Infect Dis. 210: 558-566.